Table 2.

Overall survival (OS) and progression-free survival (PFS) for patients by the degree of immunoparesis

		Old trials (MIV, MV, MVI and MVIII)				Recent Trials (MIX and MXI)
	Grouping (g/L)	N	Median (95% CI)	Censored	Log-rank x2, p	N	Median (95% CI)	Censored	Log-rank x2, p
OS
Polyclonal IgG levels (for non-IgG myeloma)	>4 to <6	288	2.22 (1.85–2.57)	5%	0.55, .76	367	3.84 (3.25–4.90)	53%	0.05, .98
	≥3 to ≤4	243	2.02 (1.65–2.31)	7%		287	4.02 (3.00–4.53)	54%
	<3	249	1.98 (1.62–2.39)	4%		389	3.69 (3.30–4.50)	55%
Polyclonal IgA levels (for non-IgA myeloma)	>0.3 to <0.8	509	2.42 (2.17–2.68)	5%	3.69, .16	832	4.30 (3.86–4.96)	57%	0.86, .65
	≥0.2 to ≤0.3	627	2.05 (1.86–2.17)	5%		402	4.90 (4.02–5.44)	59%
	<0.2	322	2.29 (2.01–2.63)	5%		734	4.29 (3.94–4.96)	58%
Polyclonal IgM levels (for non-IgM myeloma)	>0.2 to <0.5	689	2.48 (2.21–2.72)	7%	17.36, .0002	918	4.92 (4.49–5.52)	60%	9.92, .007
	>0.1 to ≤0.2	656	2.17 (1.94–2.36)	4%		963	4.26 (3.89–4.72)	57%
	≤0.1	728	2.05 (1.85–2.25)	6%		974	4.02 (3.61–4.33)	55%
PFS
Polyclonal IgG levels (for non-IgG myeloma)	>4 to <6	287	1.42 (1.28–1.57)	2%	0.02, .99	367	1.75 (1.55–1.91)	29%	2.91, .23
	≥3 to ≤4	243	1.24 (1.09–1.52)	3%		287	1.80 (1.63–2.07)	31%
	<3	246	1.35 (1.20–1.54)	1%		389	1.65 (1.42–1.86)	27%
Polyclonal IgA levels (for non-IgA myeloma)	>0.3 to <0.8	509	1.56 (1.38–1.73)	3%	5.47, .07	832	1.85 (1.69–2.00)	31%	1.24, .54
	≥0.2 to ≤0.3	625	1.52 (1.38–1.65)	2%		402	1.82 (1.59–2.01)	28%
	<0.2	322	1.61 (1.38–1.79)	2%		734	1.81 (1.65–1.95)	29%
Polyclonal IgM levels (for non-IgM myeloma)	>0.2 to <0.5	688	1.62 (1.50–1.71)	3%	16.29, .0003	918	1.97 (1.78–2.17)	33%	17.09, .0002
	>0.1 to ≤0.2	655	1.51 (1.36–1.65)	2%		963	1.79 (1.64–1.91)	30%
	≤0.1	725	1.39 (1.25–1.53)	3%		974	1.71 (1.58–1.82)	27%